Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer
Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al.
European Urology (2020) Vol. 78, Iss. 5, pp. 652-656
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Silke Gillessen, Alberto Bossi, Ian D. Davis, et al.
European Journal of Cancer (2023) Vol. 185, pp. 178-215
Open Access | Times Cited: 102
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
Evan W. Warner, Kim Van der Eecken, Andrew J. Murtha, et al.
Nature Cancer (2024) Vol. 5, Iss. 1, pp. 114-130
Closed Access | Times Cited: 19
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline
Evan Y. Yu, R. Bryan Rumble, Neeraj Agarwal, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 4
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Maria Adamaki, Vassilios Zoumpourlis
Pharmacology & Therapeutics (2021) Vol. 228, pp. 107932-107932
Closed Access | Times Cited: 90
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
Umang Swami, Ryon P. Graf, Roberto Nussenzveig, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 22, pp. 4917-4925
Open Access | Times Cited: 43
Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review
Shigekatsu Maekawa, Ryo Takata, Wataru Obara
Cancers (2024) Vol. 16, Iss. 3, pp. 523-523
Open Access | Times Cited: 11
The tumor microenvironment and immune responses in prostate cancer patients
J. Kwon, Richard J. Bryant, Ellen Parkes
Endocrine Related Cancer (2021) Vol. 28, Iss. 8, pp. T95-T107
Open Access | Times Cited: 55
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings
Matteo Ferro, Giuseppe Lucarelli, Felice Crocetto, et al.
Critical Reviews in Oncology/Hematology (2020) Vol. 157, pp. 103198-103198
Closed Access | Times Cited: 42
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity
Ivana Grbeša, Michael A. Augello, Deli Liu, et al.
Cell Reports (2021) Vol. 36, Iss. 10, pp. 109625-109625
Open Access | Times Cited: 40
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert Holler, Wei Fu, et al.
JCO Precision Oncology (2021), Iss. 5, pp. 1200-1220
Open Access | Times Cited: 36
Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review
Kim Van der Eecken, Jan Vanwelkenhuyzen, Matthew P. Deek, et al.
European Urology Oncology (2021) Vol. 4, Iss. 6, pp. 914-923
Closed Access | Times Cited: 36
Genomic Profiling of Prostate Cancer: An Updated Review
Koji Hatano, Norio Nonomura
The World Journal of Men s Health (2021) Vol. 40, Iss. 3, pp. 368-368
Open Access | Times Cited: 34
Clinical and genomic features of SPOP‐mutant prostate cancer
Mari Nakazawa, Mike Fang, Catherine H. Marshall, et al.
The Prostate (2021) Vol. 82, Iss. 2, pp. 260-268
Open Access | Times Cited: 33
Deregulation of SPOP in Cancer
Hui Zhang, Xiaofeng Jin, Haojie Huang
Cancer Research (2022) Vol. 83, Iss. 4, pp. 489-499
Open Access | Times Cited: 27
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
Axel S. Merseburger, Nick Waldron, María J. Ribal, et al.
European Urology (2021) Vol. 79, Iss. 4, pp. 519-529
Closed Access | Times Cited: 31
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
Alok K. Tewari, Alexander T. M. Cheung, Jett Crowdis, et al.
Cell Reports (2021) Vol. 36, Iss. 10, pp. 109665-109665
Open Access | Times Cited: 31
CHD1, a multifaceted epigenetic remodeler in prostate cancer
Haoyan Li, Loraine Gigi, Di Zhao
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis
Martino Pedrani, Giuseppe Salfi, Sara Merler, et al.
European Urology Oncology (2024) Vol. 7, Iss. 6, pp. 1199-1215
Open Access | Times Cited: 4
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy
Georges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
Prostate Cancer and Prostatic Diseases (2025)
Closed Access
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype
Dali Tong
Critical Reviews in Oncology/Hematology (2021) Vol. 163, pp. 103370-103370
Closed Access | Times Cited: 26
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression
Lei Shi, Yuqian Yan, Yundong He, et al.
Cancer Research (2021) Vol. 81, Iss. 13, pp. 3593-3606
Open Access | Times Cited: 24
Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
Leandro Blas, Masaki Shiota, Masatoshi Eto
Cancer Treatment and Research Communications (2022) Vol. 32, pp. 100606-100606
Open Access | Times Cited: 17
De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
Claudia Piombino, Marco Oltrecolli, Elena Tonni, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 4945-4945
Open Access | Times Cited: 10
Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model
Yanlong Zhang, Ruiqiao Zhang, Fangzhi Liang, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 25
SPOP-mutant prostate cancer: Translating fundamental biology into patient care
Tiziano Bernasocchi, Jean‐Philippe Theurillat
Cancer Letters (2021) Vol. 529, pp. 11-18
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top